04May 2024
Real-world Efficacy of Ranibizumab, Aflibercept, and Dexamethasone Implant in Treating Diabetic Macular Edema

Real-world Efficacy of Ranibizumab, Aflibercept, and Dexamethasone Implant in Treating Diabetic Macular Edema

In a study comparing treatments for diabetic macular edema (DME), researchers analyzed the outcomes of ranibizumab, aflibercept, and dexamethasone implant monotherapy in real-life conditions. Results showed significant improvements in visual acuity (BCVA) and central retinal thickness (CRT) in all groups at 12 months. Notably, ranibizumab and aflibercept demonstrated superior BCVA outcomes compared to dexamethasone, particularly in eyes with initially good vision. However, no significant differences were observed in eyes with initially poor vision. No serious complications were reported. These findings suggest ranibizumab and aflibercept as effective treatments for DME, especially in maintaining or improving visual acuity.

  • #ophthalmology

Like

Save

Share